Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects.

@article{Antonarakis2010CombiningLC,
  title={Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects.},
  author={Emmanuel S Antonarakis and Michael Anthony Carducci},
  journal={Expert opinion on investigational drugs},
  year={2010},
  volume={19 2},
  pages={
          311-4
        }
}
Prostate GVAX((R)) is an allogeneic cell-based prostate cancer vaccine engineered to secrete GM-CSF. The release of GM-CSF by this immunotherapy serves to recruit dendritic cells, which then present tumor antigens to T cells, thus initiating antitumor immune responses. However, preclinical data show that, when used alone, cell-based immunotherapy is generally unable to break specific T-cell tolerance in tumor-bearing hosts. The study by Wada and colleagues employed an autochthonous prostate… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 10 REFERENCES

A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer

  • E Small, T Demkow, WR Gerritsen
  • Genitourin Cancer Symp,
  • 2009
2 Excerpts

A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer

  • C Higano, F Saad, B Somer
  • Genitourin Cancer Symp,
  • 2009
2 Excerpts

Similar Papers

Loading similar papers…